Dare Bioscience, Inc. — Director's Dealing 2014

Apr 10, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2014-04-10

Reporting Person: Roberts Karen Lynn (Sr VP Finance & Administrat)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$3.34	2021-01-27	Common Stock (10559)		Direct
Stock Option (right to buy)	$3.77	2022-01-24	Common Stock (13786)		Direct
Stock Option (right to buy)	$3.92	2022-12-18	Common Stock (14693)		Direct
Stock Option (right to buy)	$10.59	2024-01-09	Common Stock (13786)		Direct
Stock Option (right to buy)	$3.34	2020-03-03	Common Stock (9650)		Direct

Footnotes

F1: This option was granted on January 28, 2011. This option vested as to 25% of the underlying shares on December 31, 2011, and vests as to an additional 2.08333% of the shares monthly thereafter through and including December 31, 2014.

F2: Reflects a 1-for-14.5074 reverse stock split effected on March 31, 2014.

F3: This option was granted on January 25, 2012. This option vested as to 25% of the underlying shares on December 31, 2012, and vests as to an additional 2.08333% of the shares monthly thereafter through and including December 31, 2015.

F4: This option was granted on December 19, 2012. This option vested as to 25% of the underlying shares on December 31, 2013, and vests as to an additional 2.08333% of the shares monthly thereafter through and including December 31, 2016.

F5: This option was granted on January 10, 2014. The shares under this option vest in 48 equal monthly installments from and after December 31, 2013 through December 31, 2017.

F6: This option was granted on March 4, 2010. This option was fully vested as of January 4, 2014.

F7: Reflects a reduction in exercise price on January 28, 2011 from $5.80 per share to $3.34 per share.